These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 12895193)

  • 21. Genetic susceptibility to acquired long QT syndrome: pharmacologic challenge in first-degree relatives.
    Kannankeril PJ; Roden DM; Norris KJ; Whalen SP; George AL; Murray KT
    Heart Rhythm; 2005 Feb; 2(2):134-40. PubMed ID: 15851285
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Reckless administration of QT interval-prolonging agents in elderly patients with drug-induced torsade de pointes.
    Jackobson G; Carmel NN; Lotan D; Kremer A; Justo D
    Z Gerontol Geriatr; 2018 Jan; 51(1):41-47. PubMed ID: 27878411
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sex differences in drug-induced changes in ventricular repolarization.
    Vicente J; Johannesen L; Mason JW; Pueyo E; Stockbridge N; Strauss DG
    J Electrocardiol; 2015; 48(6):1081-7. PubMed ID: 26324176
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A case series of drug-induced long QT syndrome and Torsade de Pointes.
    Tong KL; Lau YS; Teo WS
    Singapore Med J; 2001 Dec; 42(12):566-70. PubMed ID: 11989578
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dose-related effects of methadone on QT prolongation in a series of patients with torsade de pointes.
    Krantz MJ; Kutinsky IB; Robertson AD; Mehler PS
    Pharmacotherapy; 2003 Jun; 23(6):802-5. PubMed ID: 12820821
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Drug-induced QT prolongation: Concordance of preclinical anesthetized canine model in relation to published clinical observations for ten CiPA drugs.
    Koshman YE; Wilsey AS; Bird BM; Endemann AL; Sadilek S; Treadway J; Martin RL; Polakowski JS; Gintant GA; Mittelstadt SW
    J Pharmacol Toxicol Methods; 2020; 103():106871. PubMed ID: 32360993
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Long QT syndrome induced by cordaron and quinidine].
    Mironchik EV; Dolgosheĭ TS; Liskovich TG; Madeshkina GA; Kokhkovski AB; Tyshchenko AD
    Klin Med (Mosk); 2007; 85(3):69-71. PubMed ID: 17523411
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetic-pharmacodynamic modelling of QT interval prolongation following citalopram overdoses.
    Friberg LE; Isbister GK; Duffull SB
    Br J Clin Pharmacol; 2006 Feb; 61(2):177-90. PubMed ID: 16433872
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Proarrhythmic effects of the class III agent almokalant: importance of infusion rate, QT dispersion, and early afterdepolarisations.
    Carlsson L; Abrahamsson C; Andersson B; Duker G; Schiller-Linhardt G
    Cardiovasc Res; 1993 Dec; 27(12):2186-93. PubMed ID: 8313427
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Drug-induced QT prolongation in women during the menstrual cycle.
    Rodriguez I; Kilborn MJ; Liu XK; Pezzullo JC; Woosley RL
    JAMA; 2001 Mar; 285(10):1322-6. PubMed ID: 11255387
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Torsade de pointes tachycardia during administration of quinidine and verapamil in atrial fibrillation].
    Karch M; Schmitt C; Plewan A; Schmidt G; Schömig A
    Herz; 1997 Feb; 22(1):51-6. PubMed ID: 9173039
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Predicting torsade de pointes in acquired long QT syndrome: optimal identification of critical QT interval prolongation.
    Chiladakis J; Kalogeropoulos A; Zagkli F; Koutsogiannis N; Chouchoulis K; Alexopoulos D
    Cardiology; 2012; 122(1):3-11. PubMed ID: 22626988
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cardiac safety, drug-induced QT prolongation and torsade de pointes (TdP).
    Ritter JM
    Br J Clin Pharmacol; 2012 Mar; 73(3):331-4. PubMed ID: 22329611
    [No Abstract]   [Full Text] [Related]  

  • 34. Drug-induced QT Interval Prolongation in the Intensive Care Unit.
    Etchegoyen CV; Keller GA; Mrad S; Cheng S; Di Girolamo G
    Curr Clin Pharmacol; 2017; 12(4):210-222. PubMed ID: 29473523
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Simple-to-use, reference criteria for revealing drug-induced QT interval prolongation in conscious dogs.
    Schmitt MW; Von Landenberg F; Poth H; Wimmer E; Goddemeier T; Cavero I
    Eur J Pharmacol; 2007 Jan; 554(1):46-52. PubMed ID: 17112506
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sex differences in ventricular repolarization: from cardiac electrophysiology to Torsades de Pointes.
    Abi-Gerges N; Philp K; Pollard C; Wakefield I; Hammond TG; Valentin JP
    Fundam Clin Pharmacol; 2004 Apr; 18(2):139-51. PubMed ID: 15066127
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Is gender a risk factor for adverse drug reactions? The example of drug-induced long QT syndrome.
    Drici MD; Clément N
    Drug Saf; 2001; 24(8):575-85. PubMed ID: 11480490
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Serum quinidine concentrations and effect on QT dispersion and interval.
    Mathis AS; Gandhi AJ
    Ann Pharmacother; 2002; 36(7-8):1156-61. PubMed ID: 12086546
    [TBL] [Abstract][Full Text] [Related]  

  • 39. QT interval dynamics and triggers for QT prolongation immediately following cardiac arrest.
    Cohen RB; Dai M; Aizer A; Barbhaiya C; Peterson C; Bernstein S; Park DS; Spinelli M; Chinitz LA; Jankelson L
    Resuscitation; 2021 May; 162():171-179. PubMed ID: 33652119
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of hypokalaemia on arrhythmogenic risk of quinidine in rats.
    Hirota M; Ohtani H; Hanada E; Kotaki H; Sawada Y; Iga T
    Life Sci; 1998; 62(24):2159-69. PubMed ID: 9627074
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.